ProtoKinetix, Inc.

ProtoKinetix, Inc. is a U.S.-based biotechnology company focused on research and development of AFGPs, or anti-freeze glycoproteins, marketed under the AAGP® trademark. The company’s work centers on advancing this molecule toward commercial use in targeted healthcare and other medical applications, with research, validation, and partnering activities as core parts of the business.

0.05

0.05

— ProtoKinetix, Inc.
%
AAGP® research and development70% Scientific work to validate and advance the AAGP® molecule for medical use.
Commercialization and partnering20% Activities to secure collaborators and commercial entities for market entry.
Intellectual property and patent activity10% Patent-related work and protection of the AAGP® technology platform.

ProtoKinetix does not appear to sell a broad commercial product set today; instead, its counterparties are mainly...

  • Research collaboratorsprimary

    Universities, labs, and scientific partners that help test and validate AAGP®.

  • Commercial partnersprimary

    Business entities that may help fund, license, or commercialize AAGP®.

  • Healthcare solution end usersemerging

    Future buyers of targeted health care applications built on AAGP®.

  • Grant and institute partnerssecondary

    Institutions that may support continued studies through grants or programs.

ProtoKinetix is headquartered in the United States and reports U.S. GAAP financial statements...

  • •Headquartered in the United States
  • •Cross-border tax exposure referenced for the U.S. and Canada
  • •North American focus for research and commercialization efforts
  • •No disclosed country revenue split in the excerpts
  • •Geography is driven by partners and research activity, not manufacturing

The company’s strategy is to move AAGP® from scientific research toward practical commercial validation and eventual...

01
Commercial validation of AAGP®short-term

The molecule must be validated before it can support meaningful commercialization.

02
Partnering and cost sharingshort-term

External partners can reduce funding needs and accelerate development.

03
AAGP® commercializationmedium-term

Longer-term value depends on turning the molecule into marketable applications.

ProtoKinetix faces the typical risks of an early-stage biotechnology company: uncertain scientific outcomes, dependence...

critical

Going concern and funding dependence

The company has limited cash and relies on external financing to continue operations.

Scope
Operating continuity and development funding
Materiality
high
high

Scientific and development failure

AAGP® may not achieve the validation needed for commercial use.

Scope
Core technology and future monetization
Materiality
high
high

Dilution from common stock issuance

The company intends to fund itself by selling common stock.

Scope
Shareholder dilution and financing terms
Materiality
high
medium

Retention of key scientific consultants

The business depends on specialized expertise to advance research.

Scope
Execution of research and commercialization plans
Materiality
medium
medium

Competition and intellectual property

Competing technologies or weak IP protection could limit adoption.

Scope
AAGP® market position
Materiality
medium
Share-based compensation valuation
Can materially affect operating expenses and equity
Patent and development-related spending
Affects investing cash flow and period expenses
Going-concern assessment
Important for liquidity interpretation and disclosure
Estimates and assumptions
Can change reported expenses and financial condition

Propanc Biopharma, Inc.

PPCB · Pharmaceutical Preparations

Onconetix, Inc.

ONCO · Pharmaceutical Preparations

CYTOKINETICS INC

CYTK · Pharmaceutical Preparations

AIBOTICS, INC.

AIBT · Medicinal Chemicals & Botanical Products

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

Protagenic Therapeutics, Inc.\new

PTIX · Pharmaceutical Preparations

: 29/04/2026